1.

Record Nr.

UNINA9910456892503321

Titolo

Endocrine therapies in breast cancer [[electronic resource] /] / edited by Aman U. Buzdar

Pubbl/distr/stampa

Oxford ; ; New York, : Oxford University Press, 2007

ISBN

0-19-173987-1

0-19-960699-4

1-283-58075-6

9786613893208

0-19-157517-8

Descrizione fisica

1 online resource (129 p.)

Collana

Oxford oncology library

Altri autori (Persone)

BuzdarAman U

Disciplina

616.99/449071

Soggetti

Breast - Cancer - Hormone therapy

Breast - Cancer - Endocrine aspects

Electronic books.

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references and index.

Nota di contenuto

Contents; Contributors; 1 Selection of patients for endocrine therapies; 2 Ovarian ablation; 3 Antioestrogens; 4 Aromatase inhibitors in early and advanced disease; 5 Fulvestrant in metastatic disease; 6 Progestins and androgens; 7 Combined endocrine and chemotherapy in breast cancer; 8 Hormone replacement therapy in patients with a prior history of breast cancer; 9 Chemoprevention; Index; A; B; C; D; E; F; G; H; I; L; M; N; O; P; R; S; T; V; W; Z

Sommario/riassunto

Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able toreduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging